The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Maximizing Survival Benefit With Primary Prevention Implantable Cardioverter-Defibrillator Therapy in a Heart Failure Population
Open accessAbstract
Background— Although implantable cardioverter-defibrillator (ICD) therapy reduces mortality in moderately symptomatic heart failure patients with an ejection fraction ≤35%, many such patients do not require ICD shocks over long-term follow-up. Methods and Results— Using a modification of a previously validated risk prediction model based on routine clinical variables, we examined the relationship between baseline predicted mortality risk and the relative and absolute survival benefits of ICD treatment in the primary prevention Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). In the placebo arm, predicted 4-year mortality grouped into 5 equal-sized risk groups varied from 12% to 50% (c statistic=0.71), whereas the proportion of SCD in those same risk groups decreased from 52% to 24% of all deaths. ICD treatment decreased relative risk of SCD by 88% in the lowest-risk group versus 24% in the highest-risk group ( P =0.009 for interaction) and decreased relative risk of total mortality by 54% in the lowest-risk group versus no benefit (2%) in the highest-risk group ( P =0.014 for interaction). Absolute 4-year mortality reductions were 6.6%, 8.8%, 10.6%, 14.0%, and −4.9% across risk quintiles. In highest-risk patients (predicted annual mortality >20%), no benefit of ICD treatment was seen. Projected over each patient’s predicted lifespan, ICD treatment added 6.3, 4.1, 3.0, 1.9, and 0.2 additional years of life in the lowest- to highest-risk groups, respectively. Conclusions— A clinical risk prediction model identified subsets of moderately symptomatic heart failure patients in SCD-HeFT in whom single-lead ICD therapy was of no benefit and other subsets in which benefit was substantial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure
Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., Domanski, M., Troutman, C., Anderson, J., Johnson, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043399 · Cited by 6,552
Self-citationA Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities
Epstein, A. E., DiMarco, J. P., Ellenbogen, K. A., Estes, N. A. M., Freedman, R. A., Gettes, L. S., Gillinov, A. M., Gregoratos, G., Hammill, S. C., Hayes, D. L., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.032 · Cited by 2,546
WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.167586 · Cited by 2,251
Self-citationAn Assessment of Clinically Useful Measures of the Consequences of Treatment
Laupacis, A., Sackett, D. L., & Roberts, R. S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806303182605 · Cited by 1,681
Buxton, A. E., Lee, K. L., Hafley, G. E., Pires, L. A., Fisher, J. D., Gold, M. R., Josephson, M. E., Lehmann, M. H., & Prystowsky, E. N. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.04.095 · Cited by 356
Self-citationGold, M. R., Ip, J. H., Costantini, O., Poole, J. E., McNulty, S., Mark, D. B., Lee, K. L., & Bardy, G. H. (2008) · Circulation · doi:10.1161/circulationaha.107.748962 · Cited by 193
Self-citation
Cited by
Sudden cardiac death: epidemiology and risk factors
Adabag, A. S., Luepker, R. V., Roger, V. L., & Gersh, B. J. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.3 · Cited by 430
High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure
Ky, B., French, B., McCloskey, K., Rame, J. E., McIntosh, E., Shahi, P., Dries, D. L., Tang, W. H. W., Wu, A. H. B., Fang, J. C., et al. (2011) · Circulation: Heart Failure · doi:10.1161/circheartfailure.110.958223 · Cited by 376
Self-citationIles, L., Pfluger, H., Lefkovits, L., Butler, M. J., Kistler, P. M., Kaye, D. M., & Taylor, A. J. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.062 · Cited by 309
Lane, D. A., Aguinaga, L., Blomström-Lundqvist, C., Boriani, G., Dan, G.-A., Hills, M. T., Hylek, E. M., LaHaye, S. A., Lip, G. Y. H., Lobban, T., et al. (2015) · Europace · doi:10.1093/europace/euv233 · Cited by 142
Metadata
- Authors
- Levy, W. C., Lee, K. L., Hellkamp, A. S., Poole, J. E., Mozaffarian, D., Linker, D. T., Maggioni, A. P., Anand, I., Poole-Wilson, P. A., Fishbein, D. P., Johnson, G., Anderson, J., Mark, D. B., & Bardy, G. H.
- Venue
- Circulation
- Published
- 2009-09-08
- Volume
- 120
- Issue
- 10
- Pages
- 835-842
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2065712665
- Cited by
- 222
- References
- 7
- FWCI
- 14.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Maximizing Survival Benefit With Primary Prevention Implantable Cardioverter-Defibrillator Therapy in a Heart Failure Population. https://app.cochat.ai/papers/10.1161/circulationaha.108.816884
- The paper
- Levy, W. C., Lee, K. L., Hellkamp, A. S., Poole, J. E., Mozaffarian, D., Linker, D. T., Maggioni, A. P., Anand, I., Poole-Wilson, P. A., Fishbein, D. P., Johnson, G., Anderson, J., Mark, D. B., & Bardy, G. H. (2009). Maximizing Survival Benefit With Primary Prevention Implantable Cardioverter-Defibrillator Therapy in a Heart Failure Population. Circulation. https://doi.org/10.1161/circulationaha.108.816884
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.